Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline - Summary - MDSpire

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED.

  • By

  • SHANE R. KANNARR, OD

  • Christoper J. Jacquinot, OD

  • Ryan A. Cedeno, OD

  • July 1, 2025

  • 1 min

Share

Objective:

To discuss new treatment options in development for dry eye disease (DED).

Key Findings:
  • Reproxalap may reduce inflammation in DED and allergy patients.
  • AZR-MD-001 could enhance meibum quality in meibomian gland dysfunction.
  • OCS-02 targets ocular inflammation related to DED.
  • Softacort may alleviate symptoms when used with proper lid care.
Interpretation:

These emerging therapies represent a tailored approach to treating the underlying causes of dry eye disease.

Limitations:
Conclusion:

The development of these pharmaceuticals indicates progress in addressing the diverse mechanisms of dry eye disease.

Original Source(s)

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

  • by SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

  • July 1, 2025

Related Content

Dry Eye Dx and Tx: Conjunctivochalasis—The Dry Eye “Mimicker”

AAO Opens Call for Course Proposals for Academy 2026 Anaheim

The American Academy of Optometry (AAO) has opened its call for course proposals for the educational program at Academy 2026 Anaheim, inviting optometrists and educators to submit lectures, workshops, and interactive sessions for consideration.

Music May Ease Anxiety in Eye Clinics

Background music and multimedia exposure were associated with lower patient-reported anxiety in a quasi-experimental ophthalmology clinic study that used existing clinic audiovisual infrastructure at no additional cost.